Indian pharmaceutical exports have recorded a strong performance in the first eight months of FY 2025–26, underscoring the sector’s resilience amid global economic uncertainty. Exports rose by 6.5 per cent year-on-year to $20.48 billion during April–November, with Brazil and Nigeria emerging as key growth markets, according to the latest data from the Ministry of Commerce and Industry.
Brazil and Nigeria are gaining prominence as important destinations for Indian pharmaceutical products, contributing significantly to export growth during the period under review.
Nigeria emerged as one of the fastest-growing markets, adding nearly $179 million to India’s pharmaceutical export earnings and accounting for over 14 percent of total export growth. This surge reflects expanding healthcare access, increased public procurement, and growing dependence on affordable Indian generic medicines in the West African nation. Brazil also posted a notable increase, with pharmaceutical imports from India rising by close to $100 million, driven by strong demand from its large and evolving healthcare system.
Overall, the growth highlights India’s expanding global footprint as a reliable supplier of cost-effective medicines. The United States remained the largest export destination, accounting for over 31 per cent of total pharmaceutical exports. At the same time, markets such as France, the Netherlands, Canada, Germany, and South Africa maintained stable shares, contributing to a diversified export base.
India is among the world’s leading suppliers of generic medicines, exporting to over 200 countries. The sector plays a critical role in global healthcare by ensuring the availability of affordable drugs and vaccines while meeting stringent regulatory standards across major international markets.
